All In Biotech

Drug Trial Radar · NCT01423747

Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia

Last checked: Nov 20, 2026Latest source record: Jun 26, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

400

Planned (sponsor's estimate)

Start

Jul 2003

Primary completion

Sep 2011

Study completion Sep 2016

Sponsor

Lead sponsor
St. Anna KinderkrebsforschungAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
International BFM Study Group
First posted
Aug 26, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 3 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

With this protocol the ALL-SZT BFM international study group wants to evaluate whether hematopoietic stem cell transplantation (HSCT) from matched family or unrelated matched donors (MD) is equivalent to the HSCT from matched sibling donors (MSD). to evaluate the efficacy of haematopoietic stem cell transplantation (HSCT) from mismatched family or unrelated mismatched donors (MMD) as compared to HSCT from matched sibling donor (MSD) and matched donor (MD). to determine whether therapy has been carried out according to the main haematopoietic stem cell transplantation (HSCT) protocol recommendations. The standardisation of the treatment options during haematopoietic stem cell transplantation (HSCT) from different donor types aims at the achievement of an optimal comparison of survival after HSCT with survival after chemotherapy only. to prospectively evaluate and compare the incidence of acute and chronic graft- versus-host-disease (GvHD) after haematopoietic stem cell transplantation (HSCT) from matched sibling donor (MSD), from matched donor (MD) and from mismatched donor (MMD).

Conditions

  • Lymphoblastic Leukemia, Acute, Childhood;

Interventions

  • VP16Drug

    patients with MSD receive as conditioning VP16 60mg/kg/d on day -3

  • TBIRadiation

    patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning

  • VP16, ATGDrug

    patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1

  • TBIRadiation

    patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)

  • Fludarabine, OKT3, Treosulfan, ThiotepaDrug

    patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG 20mg/kd/d on day -3 to day -1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4

  • VP16, ATGDrug

    patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d

  • TBIRadiation

    patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free and overall survival after allogeneic haematopoietic stem cell transplantation (HSCT)Time frame: 14 years

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • Universitätsklinik für Kinder- und Jugendheilkunde, Klin. Abt. f. Hämato-Onkologie

    Graz, Austria

  • Universitätsklinik für Kinder- und Jugendheilkunde

    Innsbruck, Austria

  • St. Anna Kinderspital

    Vienna, Austria

  • Charité Campus Virchow- Klinikum, Klinikum der Pädiatrie, Onkologie/Hämatologie/KMT

    Berlin, Germany

  • Klinik und Poliklinik für Kinderheilkunde, Hämatologie, Onkologie

    Dresden, Germany

  • Universitätsklinikum Düsseldorf, Klinik f. Kinderonkologie, Hämatologie u. Immunologie

    Düsseldorf, Germany

  • Klinik für Kinder und Jugendliche der Universität Erlangen-Nürnberg

    Erlangen, Germany

  • Universitätsklinikum Essen, Zentrum für Kinderheilkunde, Abt. für Hämatologie/Onkologie

    Essen, Germany

  • Klinik für Kinderheilkunde III, Hämatologie und Onkologie, Johann Wolfgang Goethe Universität

    Frankfurt am Main, Germany

  • Universitätsklinikum Freiburg, Zentrum für Kinderheilkunde und Jugendmedizin, Klinik IV: Päd. Hämatologie und Onkologie

    Freiburg im Breisgau, Germany

  • Zentrum für Kinderheilkunde, Abt. Hämatologie und Onkologie

    Giessen, Germany

  • Klinkum der Med. Fakultät der Martin-Luther-Universität Halle-Wittenberg, Uni. Klinik un Poliklinik für Kinder- und Jugendmedizin

    Halle, Germany

  • Universitätsklinikum Hamburg-Eppendorf, Kinderklinik, Abt. für Hämatologie und Onkologie

    Hamburg, Germany

  • Med. Hochschule Hannover, Päd. Hämatologie und Onkologie

    Hanover, Germany

  • Universitätskinderklinik, Päd. Hämatologie, Onkologie und Immunologie

    Heidelberg, Germany

  • Klinik für Knochenmarktransplantation

    Idar-Oberstein, Germany

  • Klinik für Kinder- und Jugendmedizin

    Jena, Germany

  • Universitätsklinikum Kiel, Klinik für Allgemeine Pädiatrie

    Kiel, Germany

  • Klinikum der Universität München, Dr. von Haunersches Kinderspital, Abt. für Hämatologie / Onkologie

    München, Germany

  • Städt. Krankenhaus München-Schwabing, Universitätskinderklinik der TU

    München, Germany

  • Universitätsklinikum Münster, Klinik und Poliklinik für Kinderheilkunde, päd. Hämatologie / Onkologie

    Münster, Germany

  • Univ.-Klinik für Kinderheilkunde und Jugendmedizin

    Tübingen, Germany

  • Universitätskinderklinik

    Ulm, Germany

  • Universitätsklinik, päd. Onkologie/Stammzelltransplantation

    Würzburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.